Skip to main content

Day: March 4, 2025

Clinuvel Introduces Groundbreaking Vitiligo Program at the World’s Biggest Dermatology Meeting, AAD 2025

Written by Customer Service on . Posted in Public Companies.

MELBOURNE, Australia, March 03, 2025 (GLOBE NEWSWIRE) — World-leading photomedicine company CLINUVEL will make its début at the American Academy of Dermatology (AAD) Annual Meeting from March 7–11, with an immersive exhibition that illuminates the past, present and future of photomedicine. The 4,800-square-foot Pavilion of Photomedicine has been custom built for CLINUVEL for the AAD Meeting to provide an immersive experience on the history, evolution, and future of photomedicine, including CLINUVEL’s development program with the novel drug SCENESSE® (afamelanotide) to treat vitiligo and work with other melanocortins. Visitors will travel through five curated courts to experience CLINUVEL’s world of innovation, from the origins of their pioneering melanocortin technology to the ongoing clinical trials that are defining a new approach...

Continue reading

UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference

Written by Customer Service on . Posted in Public Companies.

MOUNTAIN VIEW, Calif., March 03, 2025 (GLOBE NEWSWIRE) — NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink Partners 2025 Global Healthcare Conference at 4:20pm ET (1:20pm PT) on Monday, March 10, 2025, in Miami, FL. Management will also host investor meetings during the conference. The presentation will be accessible via live webcast here. A webcast replay will be available for two weeks following the presentation in the Events section of NeuroPace’s Investor website at https://investors.neuropace.com. About NeuroPace, Inc. Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.